Korean J Dermatol.
2022 Dec;60(10):687-691.
A Case of Prurigo Nodularis Treated with Dupilumab
- Affiliations
-
- 1Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea
- 2Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea
Abstract
- Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by multiple nodules and papules, which are accompanied by intense pruritus. Treatment is challenging and requires a diverse approach. Recently, a few reports have described successful treatment of PN with dupilumab. We report a case of a patient with treatment-resistant PN who was successfully treated with dupilumab. Dupilumab was administered at the standard dose: an initial induction dose of 600 mg, followed by 300 mg every 14 days. Pruritus reduced after 2 weeks and almost completely disappeared after 4 weeks of treatment.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Thalidomide Therapy on A Case of Prurigo Nodularis
- A Case of Prurigo Nodularis Treated with Narrow-band UVB and Naltrexone
- Prurigo Nodularis Occurring in Conjunction with a Common Blue Nevus
- Pemphigoid Nodularis: A Prurigo Nodularis-Like Bullous Pemphigoid
- Two Cases of Mycosis Fungoides Diagnosed during Dupilumab Treatment
